Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: Importance of the chemokine gradient

Journal for ImmunoTherapy of Cancer

Volumn 4, Issue 1, 2016, Pages 1-12

  Siddiqui, Imran ^a,c   Erreni, Marco ^a   Van Brakel, Mandy ^b   Debets, Reno ^b   Allavena, Paola ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Adoptive T cell therapy; Chemokine gradient; Chemokines; Colorectal cancer; CX3CR1

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; FRACTALKINE;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CELL TRANSFER; CHEMOTAXIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE HOMING; LYMPHOCYTE MIGRATION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TUMOR GROWTH; TUMOR VOLUME;

EID: 84991037456     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-016-0125-1     Document Type: Article

References (52)

1. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348:62-8. doi:10.1126/science.aaa4967.
2. June CH, Riddell SR, Schumacher TN. Adoptive cellular therapy: A race to the finish line. Sci Transl Med. 2015;7:280ps7. doi:10.1126/scitranslmed.aaa3643.
3. de Witte MA, Kierkels GJJ, Straetemans T, et al. Orchestrating an immune response against cancer with engineered immune cells expressing αβTCRs, CARs, and innate immune receptors: an immunological and regulatory challenge. Cancer Immunol Immunother. 2015;64:893-902. doi:10.1007/s00262-015-1710-8.
4. Melief CJM, van Hall T, Arens R, et al. Therapeutic cancer vaccines. J Clin Invest. 2015;125:3401-12. doi:10.1172/JCI80009.
5. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233-9. doi:10.1200/JCO.2008.16.5449.
6. Stevanović S, Draper LM, Langhan MM, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirustargeted tumor-infiltrating T cells. J Clin Oncol. 2015. doi: 10.1200/JCO.2014.58.9093.
7. Lehmann FM, Maurberger A, Feicht S, et al. Targeting high-grade B cell lymphoma with CD19-specific T cells. Int J Cancer. 2014;135:1153-64. doi:10.1002/ijc.28760.
8. Siddiqi T, Rosen ST. Novel Biologic Agents for Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia-Part 2: Adoptive Cellular Immunotherapy, Small-Molecule Inhibitors, and Immunomodulation. Oncology (Williston Park). 2015;29:299-308.
9. Restifo NPN, Dudley MEM, Rosenberg SAS. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012;12:269-81. doi:10.1038/nri3191.
10. Duong CPM, Yong CSM, Kershaw MH, et al. Cancer immunotherapy utilizing gene-modified T cells: from the bench to the clinic. Mol Immunol. 2015. doi: 10.1016/j.molimm.2014.12.009.
11. Kunert A, Straetemans T, Govers C, et al. TCR-engineered T cells meet new challenges to treat solid tumors: choice of antigen, T cell fitness, and sensitization of tumor milieu. Front Immunol. 2013;4:363. doi:10.3389/fimmu.2013.00363.
12. Melero I, Rouzaut A, Motz GT, Coukos G. T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discovery. 2014;4:522-6. doi:10.1158/2159-8290.CD-13-0985.
13. Kim ST, Jeong H, Woo OH, et al. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. Am J Clin Oncol. 2013;36:224-31. doi:10.1097/COC.0b013e3182467d90.
14. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960-4. doi:10.1126/science.1129139.
15. Masopust D, Schenkel JM. The integration of T cell migration, differentiation and function. Nat Rev Immunol. 2013;13:309-20. doi:10.1038/nri3442.
16. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science. 1996; 272:60-6.
17. Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Immunology. 1999;18: 593-620. doi:10.1146/annurev.immunol.18.1.593.
18. Kershaw MH, Wang G, Westwood JA, et al. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther. 2002;13:1971-80. doi:10.1089/10430340260355374.
19. Slaney CY, Kershaw MH, Darcy PK. Trafficking of T cells into tumors. Cancer Res. 2014;74:7168-74. doi:10.1158/0008-5472.CAN-14-2458.
20. Craddock JA, Lu A, Bear A, et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother. 2010;33:780-8. doi:10.1097/CJI.0b013e3181ee6675.
21. Moon EK, Carpenito C, Sun J, et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res. 2011;17:4719-30. doi:10.1158/1078-0432.CCR-11-0351.
22. Xu Y, Hyun Y-M, Lim K, et al. Optogenetic control of chemokine receptor signal and T-cell migration. Proc Natl Acad Sci. 2014;111:6371-6. doi:10.1073/pnas.1319296111.
23. Peng W, Ye Y, Rabinovich BA, et al. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res. 2010;16:5458-68. doi:10.1158/1078-0432.CCR-10-0712.
24. Hickman HD, Reynoso GV, Ngudiankama BF, et al. CXCR3 chemokine receptor enables local CD8(+) T cell migration for the destruction of virusinfected cells. Immunity. 2015;42:524-37. doi:10.1016/j.immuni.2015.02.009.
25. Asai H, Fujiwara H, An J, et al. Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double genemodified to express WT1-specific T-cell receptor. PLoS ONE. 2013;8: e56820. doi:10.1371/journal.pone.0056820.
26. Müller N, Michen S, Tietze S, et al. Engineering NK cells modified with an EGFRvIII-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12/SDF-1α-secreting glioblastoma. J Immunother. 2015;38:197-210. doi:10.1097/CJI.0000000000000082.
27. Xu X, Wang Y, Chen J, et al. High expression of CX3CL1/CX3CR1 axis predicts a poor prognosis of pancreatic ductal adenocarcinoma. J Gastrointest Surg. 2012. doi: 10.1007/s11605-012-1921-7.
28. Tsang JYS, Ni Y-B, Chan S-K, et al. CX3CL1 expression is associated with poor outcome in breast cancer patients. Breast Cancer Res Treat. 2013;140: 495-504. doi:10.1007/s10549-013-2653-4.
29. Hyakudomi M, Matsubara T, Hyakudomi R, et al. Increased expression of fractalkine is correlated with a better prognosis and an increased number of both CD8+ T cells and natural killer cells in gastric adenocarcinoma. Ann Surg Oncol. 2008;15:1775-82. doi:10.1245/s10434-008-9876-3.
30. Brueckmann M, Borggrefe M. Therapeutic potential of fractalkine: a novel approach to metastatic colon cancer. Gut. 2007;56:314-6. doi:10.1136/gut.2006.103317.
31. Erreni M, Siddiqui I, Marelli G, et al. The Fractalkine-receptor axis improves human colorectal cancer prognosis by limiting tumor metastatic dissemination. J Immunol. 2015. doi: 10.4049/jimmunol.1501335.
32. Kostadinova FI, Baba T, Ishida Y, et al. Crucial involvement of the CX3CR1-CX3CL1 axis in dextran sulfate sodium-mediated acute colitis in mice. J Leukoc Biol. 2010;88:133-43. doi:10.1189/jlb.1109768.
33. D'Haese JG, Demir IE, Friess H, Ceyhan GO. Fractalkine/CX3CR1: why a single chemokine-receptor duo bears a major and unique therapeutic potential. Expert Opin Ther Targets. 2010;14:207-19. doi:10.1517/14728220903540265.
34. Fraticelli P, Sironi M, Bianchi G, et al. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Investig. 2001;107:1173-81. doi:10.1172/JCI11517.
35. Lucas AD, Chadwick N, Warren BF, et al. The transmembrane form of the CX3CL1 chemokine fractalkine is expressed predominantly by epithelial cells in vivo. Am J Pathol. 2001;158:855-66. doi:10.1016/S0002-9440(10)64034-5.
36. Goda S, Imai T, Yoshie O, et al. CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms. J Immunol. 2000;164:4313-20.
37. Marchesi F, Piemonti L, Fedele G, et al. The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res. 2008;68:9060-9. doi:10.1158/0008-5472.CAN-08-1810.
38. Jensen MC, Riddell SR. Designing chimeric antigen receptors to effectively and safely target tumors. Curr Opin Immunol. 2015;33:9-15. doi:10.1016/j.coi.2015.01.002.
39. Geng D, Kaczanowska S, Tsai A, et al. TLR5 ligand-secreting T cells reshape the tumor microenvironment and enhance antitumor activity. Cancer Res. 2015;75:1959-71. doi:10.1158/0008-5472.CAN-14-2467.
40. Balkwill FF. Cancer and the chemokine network. Nat Rev Cancer. 2004;4: 540-50. doi:10.1038/nrc1388.
41. Mantovani A, Savino B, Locati M, et al. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 2010;21:27-39. doi:10.1016/j.cytogfr.2009.11.007.
42. Zsiros E, Duttagupta P, Dangaj D, et al. The ovarian cancer chemokine landscape is conducive to homing of vaccine-primed and CD3/CD28-costimulated T cells prepared for adoptive therapy. Clin Cancer Res. 2015. doi: 10.1158/1078-0432.CCR-14-2777.
43. Harlin H, Meng Y, Peterson AC, et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 2009;69: 3077-85. doi:10.1158/0008-5472.CAN-08-2281.
44. Hong M, Puaux A-L, Huang C, et al. Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res. 2011;71:6997-7009. doi:10.1158/0008-5472.CAN-11-1466.
45. Straetemans T, Berrevoets C, Coccoris M, et al. Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment. Mol Ther. 2015;23:396-406. doi:10.1038/mt.2014.215.
46. Fong AM, Robinson LA, Steeber DA, et al. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med. 1998;188:1413-9.
47. Muehlhoefer A, Saubermann LJ, Gu X, et al. Fractalkine is an epithelial and endothelial cell-derived chemoattractant for intraepithelial lymphocytes in the small intestinal mucosa. J Immunol. 2000;164:3368-76.
48. Siddiqui I, Mantovani A, Allavena P. Adoptive T-cell therapy: optimizing chemokine receptor-mediated homing of T cells in cancer immunotherapy. Berlin, Heidelberg: Springer Berlin Heidelberg; 2014. p. 263-82.
49. Straetemans T, Coccoris M, Berrevoets C, et al. T-cell receptor gene therapy in human melanoma-bearing immune-deficient mice: human but not mouse T cells recapitulate outcome of clinical studies. Hum Gene Ther. 2012;23:187-201. doi:10.1089/hum.2010.126.
50. Erreni M, Solinas G, Brescia P, et al. Human glioblastoma tumours and neural cancer stem cells express the chemokine CX3CL1 and its receptor CX3CR1. Eur J Cancer. 2010:1-10. doi: 10.1016/j.ejca.2010.07.022.
51. Lamers CHJ, Willemsen RA, van Elzakker P, et al. Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer. Cancer Gene Ther. 2006;13:503-9. doi:10.1038/sj.cgt.7700916.
52. Straetemans T, van Brakel M, van Steenbergen S, et al. TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets. Clin Dev Immunol. 2012;2012:586314. doi:10.1155/2012/586314.